Efficacy and Acceptability of RUTFs in Indonesia

Severe Acute Malnutrition Clinical Trial

Official title:

Efficacy and Acceptability of Ready-to-use Therapeutic Foods (RUTFs) in Indonesia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05614505
• Other study ID #: RUTF_2021_Impact
• Status: Completed
• Phase: N/A
• Start date: July 15, 2021
• Est. completion date: January 25, 2022

Study information

• Verified date: November 2022
• Source: Institut de Recherche pour le Developpement
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Severe wasting or Severe Acute Malnutrition (SAM) continues to be a major public health problem in Indonesia, affecting more than 2 million children under 5 years old. A new approach to treat SAM is called Community-based management of acute malnutrition (CMAM), which has been designed to maximize the coverage and successful treatment of children with SAM, by providing Ready to Use Therapeutic Food (RUTF) through out-patient treatment. Since 2019, UNICEF has been working intensively to facilitate the local production of RUTF. This present study aims to assess the acceptability and efficacy of three locally produced RUTFs compared to the standard peanut based RUTF.

The study will be implemented in Bogor district. A total of 300 children with uncomplicated SAM, aged 6-59 months old, meeting the inclusion criteria will be included in the study. This study is designed as a randomized controlled trial. The children will be allocated to one of the five intervention (1 control, 4 experimental) arms. Each child will receive one type of RUTF product for eight consecutive weeks. The ration given to a child will be based on the need for an intake of ~ 170 kcal/kg BW/day. Data will be collected at baseline, at weekly intervals and at exit. The primary outcome of interest for the efficacy study is the relative weight gain of children consuming each of the local RUTFs compared with those consuming the standard RUTF. The primary outcome of the acceptability of the RUTFs will be the amount of product consumed during the eight-week efficacy trial.

Differences in weight and height gain will be analyzed using ANCOVA, controlling for age, gender, food intake, and morbidity. Repeated measurement statistics will be used to analyze differences in growth patterns over the eight-week intervention.

Description:

OBJECTIVES This study aims to assess the acceptability and efficacy to increase weight and mid upper arm circumference of children aged 6-59 months with severe acute malnutrition (SAM), of three locally produced RUTFs compared to the standard peanut based RUTF. The study will be implemented in Bogor district.

METHODOLOGY Subjects inclusion criteria are reported elsewhere.

Sample Size Calculation If the Indonesian RUTFs fulfil the WHO requirement of an average increase of 4 g/kg BW/day, a sample size of 60 children per group would allow detecting a 20% difference between control and intervention products, assuming a SD of 1.6 g/kg BW, a study design effect of 1.0, a significance of 0.05, a power of 0.80. If children fail to reach this 4 g/kg BW target and only gain 2 g/kg BW/day, the sample size would still allow detection of a 30% difference between the control product and the local product. Since it will be a five-armed intervention, a total of 300 SAM children will be recruited in Bogor district.

Anthropometric and Hemoglobin Measurements Training The training on anthropometric measurements will include repeated practice and comparison of intra- and inter-observer variation to ensure that the field team will have excellent skills in conducting the anthropometric measurements.

Hemoglobin concentration will be measured using Hemocue 201+ device by (or under direct supervision of) a medical doctor, trained in the use of the equipment.

Study Design This study is designed as an individually randomised controlled trial. Parents will be informed of the purpose, risks and benefits of the study and asked to sign the informed consent prior to inclusion of their child in the study.

Each child will be randomly allocated to one of the five intervention arms.

Acceptability Study The primary outcome of the acceptability of the RUTFs will be the amount of product consumed during the 8-week efficacy trial (long-term acceptability). An average consumption of at least 50% of the offered product during the 8-week efficacy trial will be considered acceptable.

The secondary outcome of the acceptability study will be the consumption velocity of the RUTFs during the appetite test (short-term acceptability; see below).

Efficacy Study The primary outcome of interest for the efficacy study is the relative weight gain of children consuming each of the local RUTFs compared with those consuming the standard RUTF. A difference of 20% in weight gain will be considered as physiologically significant.

Randomization Prior to the appetite test, selected children with uncomplicated SAM will be randomized to one of the five intervention arms. The randomization list is made prior to recruitment by a member of the research team not present in the field (FTW). Children randomized to one arm will receive the standard RUTF product, and the other four arms will each receive one of four local RUTFs.

Appetite Test The day after the screening, selected children will need to pass an appetite test prior to enrolment in the intervention.

Design Each child will receive one type of RUTF products for eight consecutive weeks. Data will be collected at baseline, at weekly intervals and at exit. Children who completely refuse to eat the RUTF they have been allocated to for more than 4 days/week, for 2 consecutive weeks, or children who lose or do not gain weight during 2 consecutive weekly visits, and/or develop allergic reaction and clinical symptoms during the course of the study will be dropped from the study and will be referred to the Puskesmas for treatment.

A weekly supply of RUTF will be supplied during each of the weekly check-up visits.

Baseline data General information on socio-economic status of the family, ethnicity, educational level of both parents, household food security, IYCF including 24 h food recall, use of micronutrient supplements (vitamin A, iron, syrup) and supplementary foods (PMT/Local PMT), morbidity history and current morbidity, duration of pregnancy, birth weight, immunization status, deworming, sex and age of the child, will be collected at baseline, in addition to height/length, weight, MUAC and hemoglobin concentration. All data will be recorded using a digital questionnaire on tablet computers.

Monitoring The daily amount of RUTF intake of each child will be recorded by the mother/caregiver in a monitoring book provided by the study team. The field team will visit each child on a weekly basis to monitor the feeding and intake recording by the mother/caregiver, as well as any intra-household sharing of the RUTF.

In addition to the weekly home visits, the PL will maintain regular daily communication with the mothers/caregivers through text messages.

Data Analysis The baseline, monitoring, and endline data will be entered in a digital questionnaire by the field workers. The researcher will extract data from digital questionnaire into SPSS format. Data analyses will be done using SPSS.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 300
• Est. completion date: January 25, 2022
• Est. primary completion date: December 15, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Months to 59 Months

Eligibility

Inclusion Criteria:

• Children with uncomplicated SAM (WHZ < -3 and/or MUAC <115 mm) qualified for outpatient treatment, or nutritional edema regardless of anthropometry

• Aged 6-59 months old upon enrolment

• Pass appetite test

• Never received in- and outpatient treatment on SAM (including not having consumed RUTF, F75, F100 or special medical specialty food1 in the last two months

• Willing to participate in the study (parent signed the informed consent)

Exclusion Criteria:

• Body weight < 4.0 kg;

• Uncontrolled or untreatable systemic opportunistic infection, such as active TB, HIV;

• Obvious dysmorphic features, general mental health problems (e.g., Down syndrome, etc.), other conditions interfering with normal growth;

• Participating in another clinical trial;

• Any congenital disorder that interferes with normal nutrient intake; chronic conditions including but not exclusively disorders of heart, kidney or liver (children to be screened by a physician);

• SAM with complications requiring hospital treatment (including edema +3);

• Severe anemia (Hb<7g/dL);

• Is a twin or multiple;

• Allergy to milk, nuts, legumes and/or antibiotics (Amoxicillin and Ampicillin)

Related Conditions & MeSH terms

• Malnutrition
• Severe Acute Malnutrition

Intervention

Dietary Supplement:
• Ready to use therapeutic foods
locally produced therapeutic foods

Locations

Country	Name	City	State
Indonesia	Savica	Jakarta

Sponsors (3)

Lead Sponsor	Collaborator
Institut de Recherche pour le Developpement	Savica, UNICEF

Country where clinical trial is conducted

Indonesia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	short-term acceptability	Passing the appetite test	consumption of at least 50% of RUTF provided in a 30 minute period
Primary	long-term acceptability	drop-out during the intervention	Number of children not finishing the 8 week intervention
Primary	weight gain over the 8 week intervention	weight gain (in g) over 8 week intervention	weight gain expressed as weight gain (g)/kg body weight per day over the 8 week intervention
Secondary	recovery rate	percentage of children having WHZ>-2 and/or MUAC >125 mm	from baseline to end of the 8 week intervention
Secondary	increase in height for age Z scores (HAZ)	changes in length growth among the intervention arms	from baseline to the end of the 8 week intervention
Secondary	length of stay in the treatment	Average number of day in treatment to reach recovery or drop-out	8 week intervention or shorter
Secondary	Morbidity during the intervention	number of sick days based on the weekly recall data	from baseline to 8 week intervention
Secondary	Perception	Acceptability of the product by caregivers	based on the interview with the caregiver after the 8 week intervention